

## Product References

### Clonetics™ Prostate Cells

---

#### Cells

#### PrEC<sup>+</sup>

1. Ackerstaff E, Pflug BR, Nelson JB, Bhujwala ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. *Canc Res.* 2001 May 01; 61:3599-603.
2. Agoston AT, Argani P, De Marzo AM, Hicks JL, Nelson WG. Retinoblastoma pathway dysregulation causes DNA methyltransferase 1 overexpression in cancer via MAD2-mediated inhibition of the anaphase-promoting complex. *Am J Pathol.* 2007 May; 170(5):1585-93.
3. Ahmed H, Banerjee PP, Vasta GR. Differential expression of galectins in normal, benign and malignant prostate epithelial cells: silencing of galectin-3 expression in prostate cancer by its promoter methylation. *Biochem Biophys Res Commun.* 2007 Jun 22; 358(1):241-6.
4. Asim M, Siddiqui IA, Hafeez BB, Baniahmad A, Mukhtar H. Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells. *Oncogene.* 2008 Jun 5; 27(25):3596-604.
5. Barnard RJ, Kobayashi N, Aronson WJ. Effect of diet and exercise intervention on the growth of prostate epithelial cells. *Prostate Cancer Prostatic Dis.* 2008; 11(4):362-6.
6. Bastus N, Boyd L, Mao X, Stankiewicz E, Kudahetti S, Oliver R, Berney D, Lu Y. Androgen-Induced TMPRSS2:ERG Fusion in Nonmalignant Prostate Epithelial Cells. *Cancer Res.* 2010. 70(23):9544-9548.
7. Bhosle S, Suppiah S, Molinaro R, Liang Y, Arnold R, Diehl W, Makarova N, Blackwell J, Petros J, Liotta D, Hunter E, Ly H. Evaluation of Cellular Determinants Required for In Vitro Xenotropic Murine Leukemia Virus-related Virus Entry into Human Prostate Cancer and Noncancerous Cells. 2010; 84(13):6288-6296.
8. Buettner R, Huang M, Gritsko T, Karras J, Enkemann S, Mesa T, Nam S, Yu H, Jove R. Activated signal transducers and activators of transcription 3 signaling induces CD46 expression and protects human cancer cells from complement-dependent cytotoxicity. *Mol Cancer Res.* 2007 Aug; 5(8):823-32.
9. Bullard RS, Gibson W, Bose SK, Belgrave JK, Eaddy AC, Wright CJ, Hazen-Martin DJ, Lage JM, Keane TE, Ganz TA, Donald CD. Functional analysis of the host defense peptide Human Beta Defensin-1: new insight into its potential role in cancer. *Mol Immunol.* 2008 Feb; 45(3):839-48.
10. Cai C, Chen SY, Zheng Z, Omwancha J, Lin MF, Balk SP, Shemshedini L. Androgen regulation of soluble guanylyl cyclase $\alpha$ 1 mediates prostate cancer cell proliferation. *Oncogene.* 2007; 26(11):1606-15.
11. Cangemi R, Mensah A, Albertini V, Jain A, Mello-Grand M, Chiorino G, Catapano CV, Carbone GM. Reduced expression and tumor suppressor function of the ETS transcription factor ESE-3 in prostate cancer. *Oncogene.* 2008 May 1; 27(20):2877-85.

12. Chaudhary A, Pechan T, Willett KL. Differential protein expression of peroxiredoxin I and II by benzo(a)pyrene and quercetin treatment in 22Rv1 and PrEC prostate cell lines. *Toxicol Appl Pharmacol*. 2007 Apr 15; 220(2):197-210.
13. Chaudhary J, Schmidt M. The impact of genomic alterations on the transcriptome: a prostate cancer cell line case study. *Chromosome Res*. 2006; 14(5):567-86.
14. Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, Rabbani SA. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. *Cancer*. 2006; 107(2):289-98.
15. Chen LM, Hodge GB, Guarda LA, Welch JL, Greenberg NM, Chai KX. Down-regulation of prostasin serine protease: a potential invasion suppressor in prostate cancer. *Prostate*. 2001; 48:93-103.
16. Chen Y, Hughes-Fulford M. Human prostate cancer cells lack feedback regulation of low-density lipoprotein receptor and its regulator, SREBP2. *Int J Canc*. 2001; 91:41-5.
17. Chen Y, Hughes-Fulford M. Prostaglandin E<sub>2</sub> and the protein kinase A pathway mediate arachidonic acid induction of c-fos in human prostate cancer cells. *Br J Canc*. 2000; 82(12):2000-6.
18. Cui L, Takahashi S, Tada M, Kato K, Yamada Y, Kohri K, Shirai T. Immunohistochemical detection of carcinogen-DNA adducts in normal human prostate tissues transplanted into the subcutis of athymic nude mice: results with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and 3,2'-dimethyl-4-aminobiphenyl (DMAB) and relation to Cytochrome P450s and N-acetyltransferase activity. *Canc Sci*. 2000 Jan; 91(1):52-8.
19. Denmeade SR, Jakobsen CM, Janssen S, Khan SR, Garrett ES, Lilja H, Christensen SB, Isaacs JT. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. *J Natl Cancer Inst*. 2003 Jul 02; 95(13):990-1000.
20. Dokmanovic M, Perez G, Xu W, Ngo L, Clarke C, Parmigiani RB, Marks PA. Histone deacetylase inhibitors selectively suppress expression of HDAC7. *Mol Cancer Ther*. 2007 Sep; 6(9):2525-34.
21. Doll JA, Stellmach VM, Bouck NP, Bergh ARJ, Lee C, Abramson LP, Cornwell ML, Pins MR, Borensztajn J, Crawford SE. Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. *Nat Med*. 2003 Jun; 9(6):774-80.
22. Dolloff NG, Shulby SS, Nelson AV, Stearns ME, Johannes GJ, Thomas JD, Meucci O, Fatatis A. Bone-metastatic potential of human prostate cancer cells correlates with Akt/PKB activation by  $\alpha$  platelet-derived growth factor receptor. *Oncogene*. 2005; 24:6848-54.
23. Garraway LA, Lin D, Signoretti S, Waltregny D, Dilks J, Bhattacharya N, Loda M. Intermediate basal cells of the prostate: in vitro and in vivo characterization. *Prostate*. 2003; 55(3):206-18.
24. Gibson W, Green A, Bullard RS, Eaddy AC, Donald CD. Inhibition of PAX2 expression results in alternate cell death pathways in prostate cancer cells differing in p53 status. *Cancer Lett*. 2007 Apr 18; 248(2):251-61.
25. Hara T, Honda K, Shitashige M, Ono M, Matsuyama H, Naito K, Hirohashi S, Yamada T. Mass spectrometry analysis of the native protein complex containing actinin-4 in prostate cancer cells. *Mol Cell Proteomics*. 2007; 6(3):479-91.
26. Heckl S, Regenbogen M, Sturzu A, Gharabaghi A, Feil G, Beck A, Echner H, Nagele T. Value of apoptin's 40-amino-acid C-terminal fragment for the differentiation between human tumor and non-tumor cells. *Apoptosis*. 2008 Apr; 13(4):495-508.
27. Hedlund TE, van Bokhoven A, Johannes WU, Nordeen SK, Ogden LG. Prostatic fluid concentrations of isoflavonoids in soy consumers are sufficient to inhibit growth of benign and malignant prostatic epithelial cells in vitro. *Prostate*. 2006; 66(5):557-66.
28. Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, Hawkins L, Kirn D. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. *Nature Med*. 2000 Oct; 6(10):1134-9.
29. Hu J, Straub J, Xiao D, Singh SV, Yang HS, Sonenberg N, Vatsyayan J. Phenethyl isothiocyanate, a cancer chemopreventive constituent of cruciferous vegetables, inhibits cap-dependent translation by regulating the level and phosphorylation of 4E-BP1. *Cancer Res*. 2007 Apr 15; 67(8):3569-73.
30. Huang P, Watanabe M, Kaku H, Kashiwakura Y, Chen J, Saika T, Nasu Y, Fujiwara T, Urata Y, Kumon H. Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent, OBP-

- 301, in a mouse prostate cancer model. *Cancer Gene Ther.* 2008 May; 15(5):315-22.
31. Israel K, Yu W, Sanders BG, Kline K. Vitamin E succinate induces apoptosis in human prostate cancer cells: role for Fas in vitamin E succinate-triggered apoptosis. *Nutrition Canc.* 2000; 36(1):90-100.
  32. Jiang Q, Wong J, Fyrst H, Saba JD, Ames BN.  $\gamma$ -tocopherol or combinations of vitamin E forms induce cell death in human prostate cancer cells by interrupting sphingolipid synthesis. *PNAS.* 2004 Dec 21; 101(51):17825-30.
  33. Kanagawa K, Sugimura K, Kuratsukuri K, Ikemoto S, Kishimoto T, Nakatani T. Norepinephrine activates P44 and P42 MAPK in human prostate stromal and smooth muscle cells but not in epithelial cells. *Prostate.* 2003 Sep 1; 56(4):313-8.
  34. Kasman L, Lu P, Voelkel-Johnson C. The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells. *Cancer Gene Ther.* 2007; 14(3):327-34.
  35. Kawano Y, Kitaoka M, Hamada Y, Walker MM, Waxman J, Kypka RM. Regulation of prostate cell growth and morphogenesis by Dickkopf-3. *Oncogene.* 2006; 25(49):6528-37.
  36. Keedwell RG, Zhao Y, Hannond LA, Wen K, Qin S, Atangan LI, Shurland DL, Wallace DM, Bird R, Reitmair A, Chandraratna RA, Brown G. An antagonist of retinoic acid receptors more effectively inhibits growth of human prostate cancer cells than normal prostate epithelium. *Br J Canc.* 2004 Aug; 91(3):580-8.
  37. Khan N, Afaq F, Syed DN, Mukhtar H. Fisetin, a novel dietary flavonoid causes apoptosis and cell-cycle arrest in human prostate cancer LNCaP cells. *Carcinogenesis.* 2008 Mar 20.
  38. Kim YA, Xiao D, Xiao H, Powolny AA, Lew KL, Reilly ML, Zeng Y, Wang Z, Singh SV. Mitochondria-mediated apoptosis by diallyl trisulfide in human prostate cancer cells is associated with generation of reactive oxygen species and regulated by Bax/Bak. *Mol Cancer Ther.* 2007 May; 6(5):1599-609.
  39. King KJ, Nicholson HD, Assinder SJ. Effect of increasing ration of estrogen: androgen on proliferation of normal human prostate stromal and epithelial cells, and the malignant cell line LNCaP. 2006 Jan 1; 66(1):105-14.
  40. Kleeberger W, Bova GS, Nielsen ME, Herawi M, Chuang AY, Epstein JI, Berman DM. Roles for the stem cell associated intermediate filament Nestin in prostate cancer migration and metastasis. *Cancer Res.* 2007 Oct 1; 67(19):9199-206.
  41. Klein RD, Fischer SM. Black tea polyphenols inhibit IGF-I-induced signaling through Akt in normal prostate epithelial cells and Du145 prostate carcinoma cells. *Carcinogen.* 2002; 23(1): 217-21.
  42. Kondo Y, Shen L, Cheng AS, Ahmed S, Bumber Y, Charo C, Yamochi T, Urano T, Furukawa K, Kwabi-Addo B, Gold DL, Sekido Y, Huang TH, Issa JP. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. *Nat Genet.* 2008 Jun; 40(6):741-50.
  43. Kulp SK, Chen CS, Wang DS, Chen CY, Chen CS. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. *Clin Cancer Res.* 2006; 12(17):5199-206.
  44. Kuzmin I, Gillespie JW, Protopopov A, Geil L, Dreijerink K, Yang Y, Vocke CD, Duh f-M, Zabarovsky E, Minna JD, Rhim JS, Emmert-Buck MR, Lineham WM, Lerman MI. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. *Canc Res.* 2005 Jun 15; 62:3498-502.
  45. Lau K-M, LaSpina M, Long J, Ho S-M. Expression of estrogen receptor (ER)- $\alpha$  and ER- $\beta$  in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. *Canc Res.* 2000 Jun 15; 60:3175-82.
  46. Li ZG, Yang J, Vazquez ES, Rose D, Vakar-Lopez F, Mathew P, Lopez A, Logothetis CJ, Lin SH, Navone NM. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. *Oncogene.* 2008 Jan 24; 27(5):596-603.
  47. Litvinov IV, Vander Griend DJ, Xu Y, Antony L, Dalrymple SL, Isaacs JT. Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells. *Cancer Res.* 2006; 66(17):8598-607.
  48. Liu P, Ramachandran S, Seyed MA, Scharer CD, Laycook N, Dalton WB, Williams H, Karanam S, Datta MW, Laye DL, Moreno CS. Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. *Canc Res.* 2006 Apr 15; 66:4011-9.

49. Liu X, Allen JD, Arnold JT, Blackman MR. Lycopene inhibits IGF-I signal transduction and growth in normal prostate epithelial cells by decreasing DHT-modulated IGF-I production in co-cultured reactive stromal cells. *Carcinogenesis*. 2008 Apr; 29(4):816-23.
50. Lu Y, Cai Z, Xiao G, Keller ET, Mizokami A, Yao Z, Roodman GD, Zhang J. Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. *Cancer Res*. 2007 Apr 15; 67(8):3646-53.
51. Lu Y, Cai Z, Xiao G, Liu Y, Keller ET, Yao Z, Zhang J. CCR2 expression correlates with prostate cancer progression. *J Cell Biochem*. 2007 Jun 1; 101(3):676-85.
52. Lu Y, Wang J, Xu Y, Koch AE, Cai Z, Chen X, Galson DL, Taichman RS, Zhang J. CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro. *Mol Cancer Res*. 2008 Apr; 6(4):546-54.
53. Marini P, Schmid A, Jendrossek V, Faltin H, Daniel PT, Budach W, Belka C. Irradiation specifically sensitizes solid tumour cell lines to TRAIL mediated apoptosis. *BMC Canc*. 2005; 5(5).
54. Menschikowski M, Hagelgans A, Gussakovsky E, Kostka H, Paley EL, Siegert G. Differential expression of secretory phospholipases A2 in normal and malignant prostate cell lines: regulation by cytokines, cell signaling pathways, and epigenetic mechanisms. *Neoplasia*. 2008 Mar; 10(3):279-86.
55. Meyer-Siegler KL, Iczkowski KA, Leng L, Bucala R, Vera PL. Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. *J Immunol*. 2006; 177(12):8730-9.
56. Meyer-Siegler KL, Iczkowski KA, Vera PL. Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer. *BMC Canc*. 2005; 5(73).
57. Michishita E, Garcés G, Barrett JC, Horikawa I. Upregulation of the KIAA1199 gene is associated with cellular mortality. *Cancer Lett*. 2006; 239(1):71-7.
58. Mizumachi T, Muskhelishvili L, Naito A, Furusawa J, Fan CY, Siegel ER, Kadlubar FF, Kumar U, Higuchi M. Increased distributional variance of mitochondrial DNA content associated with prostate cancer cells as compared with normal prostate cells. *Prostate*. 2008 Mar 1; 68(4):408-17.
59. Molinaro RJ, Jha BK, Malathi K, Varambally S, Chinnaiyan AM, Silverman RH. Selection and cloning of poly(rC)-binding protein 2 and Raf kinase inhibitor protein RNA activators of 2',5'-oligoadenylate synthetase from prostate cancer cells. *Nucleic Acids Res*. 2006; 34(22):6684-95.
60. Murofushi Y, Nagano S, Kamizono J, Takahashi T, Fujiwara H, Komiya S, Matsuishi T, Kosai K. Cell cycle-specific changes in hTERT promoter activity in normal and cancerous cells in adenoviral gene therapy: a promising implication of telomerase-dependent targeted cancer gene therapy. *Int J Oncol*. 2006; 29(3):681-8.
61. Nanni S, Priolo C, Grasselli A, D'Eletto M, Merola R, Moretti F, Gallucci M, De Carli P, Sentinelli S, Cianciulli AM, Mottolese M, Carlini P, Arcelli D, Helmer-Citterich M, Gaetano C, Loda M, Pontecorvi A, Bacchetti S, Sacchi A, Farsetti A. Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer. *Mol Canc Res*. 2006; 4:79-92.
62. O'Connor JC, Julian J, Lim SD, Carson DD. MUC1 expression in human prostate cancer cell lines and primary tumors. *Prostate Canc Prostat Dis*. 2005; 8:36-44.
63. Ohneseit PA, Krebiehl G, Dittmann K, Kehlbach R, Rodemann HP. Inhibition of cyclooxygenase-2 activity by celecoxib does not lead to radiosensitization of human prostate cancer cells in vitro. *Radiother Oncol*. 2007 Feb; 82(2):229-38.
64. Periyasamy S, Warriar M, Tillekeratne MP, Shou W, Sanchez ER. The immunophilin ligands cyclosporin A and FK506 suppress prostate cancer cell growth by androgen receptor-dependent and -independent mechanisms. *Endocrinology*. 2007 Oct; 148(10):4716-26.
65. Pourpak A, Landowski TH, Dorr RT. Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells. *J Pharmacol Exp Ther*. 2007 Jun; 321(3):1109-17.
66. Qian X, Ara G, Mills E, LaRochelle WJ, Lichenstein HS, Jeffers M. Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer. *Int J Cancer*. 2008 Mar 15; 122(6):1400-10.
67. Romero D, Terzic A, Conley B, Craft C, Jovanovic B, Bergan R, Vary C. Endoglin phosphorylation by ALK2 contributes to the regulation of prostate cancer cell migration. *Carcinogenesis*. 2010; 31(3):359-366.

68. Rothermund CA, Gopalakrishnan VK, Eudy JD, Vishwanatha JK. Casodex treatment induces hypoxia-related gene expression in the LNCaP prostate cancer progression model. *BMC Urol.* 2005 Mar 24; 5:5-20.
69. Russo CL, Spurr-Michaud S, Tisdale A, Pudney J, Anderson D, Gipson IK. Mucin gene expression in human male urogenital tract epithelia. *Hum Reprod.* 2006; 21(11):2783-93.
70. Sedelnikova OA, Horikawa I, Zimonjic DB, Popescu NC, Bonner WM, Barrett JC. Senescing human cells and ageing mice accumulate DNA lesions with unreparable double-strand breaks. *Nat Cell Biol.* 2004 Feb; 6(2):168-70.
71. Sen M, McHugh K, Hutzley J, Philips BJ, Dhir R, Parwani AV, Kelavkar UP. Orthotopic expression of human 15-lipoxygenase (LO)-1 in the dorsolateral prostate of normal wild-type C57BL/6 mouse causes PIN-like lesions. *Prostaglandins Other Lipid Mediat.* 2006 Oct; 81(1-2):1-13.
72. Shangary S, Ding K, Qiu S, Nikolovska-Coleska Z, Bauer JA, Liu M, Wang G, Lu Y, McEachern D, Bernard D, Bradford CR, Carey TE, Wang S. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. *Mol Cancer Ther.* 2008 Jun; 7(6):1533-42.
73. Shankar S, Chen Q, Siddiqui I, Sarva K, Srivastava RK. Sensitization of TRAIL-resistant LNCaP cells by resveratrol (3, 4', 5 tri-hydroxystilbene): molecular mechanisms and therapeutic potential. *J Mol Signal.* 2007 Aug 24; 2:7.
74. Shiau C-W, Huang J-W, Wand D-S, Weng J-R, Yang C-C, Lin C-H, Li C, Chen C-S.  $\alpha$ -tocopheryl succinate induces apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 function. *J Biol Chem.* 2006 Apr 28; 281(17):11819-25.
75. Shulby SA, Dolloff NG, Stearns ME, Meucci O, Fatatis A. CX3CR1-fractalkine expression regulated cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. *Canc Res.* 2004 Jul; 64:4693-8.
76. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, Yang A, Montironi R, McKeon F, Loda M. p63 is a prostate basal cell marker and is required for prostate development. *Am J Pathol.* 2000 Dec; 157(6):1769-75.
77. Singh S, Singh UP, Stiles JK, Grizzle WE, Lillard Jr JW. Expression and functional role of CCR9 in prostate cancer cells migration and invasion. *Clin Canc Res.* 2004; 10: 8743-50.
78. Singh SV, Choi S, Zeng Y, Hahm ER, Xiao D. Guggulsterone-induced apoptosis in human prostate cancer cells is caused by reactive oxygen intermediate dependent activation of c-Jun NH2-terminal kinase. *Cancer Res.* 2007 Aug 1; 67(15):7439-49.
79. Singh SV, Zeng Y, Xiao D, Vogel VG, Nelson JB, Dhir R, Tripathi YB. Caspase-dependent apoptosis induction by guggulsterone, a constituent of ayurvedic medicinal plant *Commiphora mukul*, in PC-3 human prostate cancer cells is mediated by Bax and Bak. *Mol Canc Ther.* 2005; 4(11): 1747-54.
80. Siva AC, Kirkland RE, Lin B, Maruyama T, McWhirter J, Yantiri-Wernimont F, Bowdish KS, Xin H. Selection of anti-cancer antibodies from combinatorial libraries by whole-cell panning and stringent subtraction with human blood cells. *J Immunol Methods.* 2008 Jan 31; 330(1-2):109-19.
81. Siva AC, Wild MA, Kirkland RE, Nolan MJ, Lin B, Maruyama T, Yantiri-Wernimont F, Frederickson S, Bowdish KS, Xin H. Targeting CUB domain-containing protein 1 with a monoclonal antibody inhibits metastasis in a prostate cancer model. *Cancer Res.* 2008 May 15; 68(10):3759-66.
82. Sroka IC, Nagle RB, Bowden GT. Membrane-type 1 matrix metalloproteinase is regulated by sp1 through the differential activation of AKT, JNK, and ERK pathways in human prostate tumor cells. *Neoplasia.* 2007 May; 9(5):406-17.
83. Subbarayan V, Krieg P, Hsi LC, Kim J, Yang P, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG. 15-Lipoxygenase-2 gene regulation by its product 15-(S)-hydroxyeicosatetraenoic acid through a negative feedback mechanism that involves peroxisome proliferator-activated receptor gamma. *Oncogene.* 2006; 25(44):6015-25.
84. Subbarayan V, Sabichi AL, Llansa N, Lippman SM, Menter DG. Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells. *Cancer Res.* 2001 Mar 15; 61(6):2720-6.
85. Subbarayan V, Xu X-C, Kim J, Yang P, Hoque A, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Inverse relationship between 15-lipoxygenase-2 and PPAR- $\gamma$  gene

- expression in normal epithelia compared with tumor epithelia. *Neoplas*. 2005 Mar; 7(3): 280-93.
86. Sumimoto M, Asano T, Asakuma J, Asano T, Nanus DM, Hayakawa M. Chemosensitization of androgen-independent prostate cancer with neutral endopeptidase. *Clin Canc Res*. 2004 Jan 1; 10:260-6.
87. Sumitomo M, Asano T, Asakuma J, Asano T, Horiguchi A, Hayakawa M. ZD1839 modulates paclitaxel response in renal cancer by blocking palitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway. *Clin Canc Res*. 2004 Jan 15; 10:794-801.
88. Suzuki K, Nishiyama T, Hara N, Yamana K, Takahashi K, Labrie F. Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer. *Prostate Cancer Prostatic Dis*. 2007; 10(3):301-6.
89. Tang XH, Suh MJ, Li R, Gudas LJ. Cell proliferation inhibition and alterations in retinol esterification induced by phytanic acid and docosahexaenoic acid. *J Lipid Res*. 2007; 48(1):165-76.
90. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB, Mehra R, Chinnaiyan AM. Role of the TMPRSS2-ERG gene fusion in prostate cancer. *Neoplasia*. 2008 Feb; 10(2):177-88.
91. Tran CP, Lin C, Yamashiro J, Reiter RE. Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. *Mol Canc Res*. 2002 Dec; 1:113-21.
92. Untergasser G, Koch HB, Menssen A, Hermeking H. Characterization of epithelial senescence by serial analysis of gene expression: identification of genes potentially involved in prostate cancer. *Canc Res*. 2002 Nov 1; 62:6255-62.
93. Uzgare AR, Xu Y, Isaacs JT. In vitro culturing and characteristics of transit amplifying epithelial cells from human prostate tissue. *J Cell Biochem*. 2004; 91(1): 196-205.
94. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS. Molecular characterization of human prostate carcinoma cell lines. *Prostate*. 2003; 57(3): 205-25.
95. Vanaja DK, Ballman KV, Morlan BW, Cheville JC, Neumann RM, Lieber MM, Tindall DJ, Young CYF. PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer. *Clin Canc Res*. 2006 Feb; 12:1128-36.
96. VanOosten RL, Earel JK, Griffith TS. Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity. *Apoptosis*. 2007; 12(3):561-71.
97. Voloshyna I, Besana A, Castillo M, Matos T, Weinstein IB, Mansukhani M, Robinson RB, Cordon-Cardo C, Feinmark SJ. TREK-1 is a novel molecular target in prostate cancer. *Cancer Res*. 2008 Feb 15; 68(4):1197-203.
98. Wang X, Klein RD. Prostaglandin E2 induces vascular endothelial growth factor secretion in prostate cancer cells through EP2 receptor-mediated cAMP pathway. *Mol Carcinog*. 2007 Nov; 46(11):912-23.
99. Watabe T, Lin M, Ide H, Donjacour AA, Cunha GR, Witte ON, Reiter RE. Growth, regeneration and tumorigenesis of the prostate activities the PSCA promoter. *PNAS*. 2002 Jan 8; 99(1):404-6.
100. Wei S, Lin LF, Yang CC, Wang YC, Chang GD, Chen H, Chen CS. Thiazolidinediones modulate the expression of beta-catenin and other cell-cycle regulatory proteins by targeting the F-box proteins of Skp1-Cul1-F-box protein E3 ubiquitin ligase independently of peroxisome proliferator-activated receptor gamma. *Mol Pharmacol*. 2007 Sep; 72(3):725-33.
101. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Freirson Jr HF, Hampton GM. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. *Canc Res*. 2001 Aug 15; 61:5974-8.
102. Weng JR, Tsai CH, Kulp SK, Wang D, Lin CH, Yang HC, Ma Y, Sargeant A, Chiu CF, Tsai MH, Chen CS. A potent indole-3-carbinol derived antitumor agent with pleiotropic effects on multiple signaling pathways in prostate cancer cells. *Cancer Res*. 2007 Aug 15; 67(16):7815-24.
103. Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, Plymate SR. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. *J Clin Invest*. 2004; 114:560-8.
104. Xiao D, Srivastava SK, Lew KL, Zeng Y, Hershberger P, Johnson CS, Trump DL, Singh SV. Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits proliferation of human prostate cancer cells

- by causing G<sub>2</sub>/M arrest and inducing apoptosis. *Carcinogen*. 2003; 24(5):891-7.
105. Xiao D, Zeng Y, Choi S, Lew KL, Nelson JB, Singh SV. Caspase-dependent apoptosis induction by phenethyl isothiocyanate, a cruciferous vegetable-derived cancer chemopreventive agent, is mediated by Bak and Bax. *Clin Canc Res*. 2005 Apr 1; 11(7):2670-9.
  106. Xie J, Nair A, Hermiston TW. A comparative study examining the cytotoxicity of inducible gene expression system ligands in different cell types. *Toxicol In Vitro*. 2008 Feb; 22(1):261-6.
  107. Yam J, Schaab A, Kreuter M, Drewe J. Piper cubeba demonstrates anti-estrogenic and anti-inflammatory properties. *Planta Med*. 2008 Feb; 74(2):142-6.
  108. Yamamoto F, Yamamoto M. Scanning copy number and gene expression on the 18q21-qter chromosomal region by the systematic multiplex PCR and reverse transcription-PCR methods. *Electrophoresis*. 2007 Jun; 28(12):1882-95.
  109. Yan M, Song Y, Wong CP, Hardin K, Ho E. Zinc deficiency alters DNA damage response genes in normal human prostate epithelial cells. *J Nutr*. 2008 Apr; 138(4):667-73.
  110. Yang CC, Wang YC, Wei S, Lin LF, Chen CS, Lee CC, Lin CC, Chen CS. Peroxisome proliferator-activated receptor gamma-independent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation. *Cancer Res*. 2007 Apr 1; 67(7):3229-38.
  111. Zhang L, Smit-McBride Z, Pan X, Rheinhardt J, Hershey JW. An oncogenic role for the phosphorylated h-subunit of human translation initiation factor eIF3. *J Biol Chem*. 2008 Aug 29; 283(35):24047-60.
  112. Zhu A, Zhang CX, Lieberman HB. Rad9 has a functional role in human prostate carcinogenesis. *Cancer Res*. 2008 Mar 1; 68(5):1267-74.
  113. Zhu H, Mazor M, Kawano Y, Walker MM, Leung HY, Armstrong K, Waxman J, Kypta RM. Analysis of Wnt gene expression in prostate cancer: mutual inhibition by WNT11 and the androgen receptor. *Canc Res*. 2004 Nov 1; 64:7918-26.

## PrSC

1. Abarzua F, Sakaguchi M, Takaishi M, Nasu Y, Kurose K, Ebara S, Miyazaki M, Namba M, Kumon H, Huh NH. Adenovirus-mediated overexpression of REIC/Dkk-3 selectively induces apoptosis in human prostate cancer cells through activation of c-Jun-NH2-kinase. *Cancer Res*. 2005 Nov 1; 65(21):9617-22.
2. Ackerstaff E, Pflug BR, Nelson JB, Bhujwala ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. *Canc Res*. 2001 May 01; 61:3599-603.
3. Albrecht M, Jiang W, Kumi-Diaka J, Lansky EP, Gommersall LM, Patel A, Mansel RE, Neeman I, Geldof AA, Campbell MJ. Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells. *J Med Food*. 2004; 7(3):274-83.
4. Bromfield GP, Meng A, Warde P, Bristow RG. Cell death in irradiated prostate epithelial cells: role of apoptotic and clonogenic cell kill. *Prostate Cancer Prostatic Dis*. 2003; 6(1):73-85.
5. Cross D, Reding DJ, Salzman SA, Zhang KQ, Catalona WJ, Burke J, Burmester JK. Expression and initial promoter characterization of PCAN1 in retinal tissue and prostate cell lines. *Med Oncol*. 2004; 21(2):145-53.
6. Cui L, Takahashi S, Tada M, Kato K, Yamada Y, Kohri K, Shirai T. Immunohistochemical detection of carcinogen-DNA adducts in normal human prostate tissues transplanted into the subcutis of athymic nude mice: results with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and 3,2'-dimethyl-4-aminobiphenyl (DMAB) and relation to Cytochrome P450s and N-acetyltransferase activity. *Canc Sci*. 2000 Jan; 91(1):52-8.
7. Doll JA, Reiher FK, Crawford SE, Pins MR, Campbell SC, Bouck NP. Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. *Prostate*. 2001; 49(4):293-305.
8. Doll JA, Stellmach VM, Bouck NP, Bergh AR, Lee C, Abramson LP, Cornwell ML, Pins MR, Borensztajn J, Crawford SE. Pigment epithelium-derived factor regulates

- the vasculature and mass of the prostate and pancreas. *Nat Med.* 2003; 9(6):774-80.
9. Fan R, Kumaravel TS, Jalali F, Marrano P, Squire JA, Bristow RG. Defective DNA strand break repair after DNA damage in prostate cancer cells: implications for genetic instability and prostate cancer progression. *Cancer Res.* 2004; 64(23):8526-33.
  10. Forbes K, Webb MA, Sehgal I. Growth factor regulation of secreted matrix metalloproteinase and plasminogen activators in prostate cancer cells, normal prostate fibroblasts and normal osteoblasts. *Prostat Can Prostat Dis.* 2003; 6(2):148-53.
  11. Garraway LA, Lin D, Signoretti S, Waltregny D, Dilks J, Bhattacharya N, Loda M. Intermediate basal cells of the prostate: in vitro and in vivo characterization. *Prostate.* 2003; 55(3):206-18.
  12. Glinsky GV, Kronen-Herzig A, Glinskii AB. Malignancy-associated regions of transcriptional activation: gene expression profiling identifies common chromosomal regions of a recurrent transcriptional activation in human prostate, breast, ovarian, and colon cancers. *Neoplasia.* 2003 May-Jun; 5(3):218-28.
  13. Gray NE, Liu X, Choi R, Blackman MR, Arnold JT. Endocrine-immune-paracrine interactions in prostate cells as targeted by phytochemicals. *Cancer Prev Res (Phila Pa).* 2009 Feb; 2(2):134-42.
  14. Haddad AQ, Venkateswaran V, Viswanathan L, Teahan SJ, Fleshner NE, Klotz LH. Novel antiproliferative flavonoids induce cell cycle arrest in human prostate cancer cell lines. *Prostate Can Prostat Dis.* 2006; 9(1):68-76.
  15. Hong S, Klein EA, Das Gupta J, Hanke K, Weight CJ, Nguyen C, Gaughan C, Kim KA, Bannert N, Kirchhoff F, Munch J, Silverman RH. Fibrils of prostatic acid phosphatase fragments boost infections with XMRV (xenotropic murine leukemia virus-related virus), a human retrovirus associated with prostate cancer. *J Virol.* 2009 Jul; 83(14):6995-7003.
  16. Huang P, Watanabe M, Kaku H, Kashiwakura Y, Chen J, Saika T, Nasu Y, Fujiwara T, Urata Y, Kumon H. Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model. *Cancer Gene Ther.* 2008 May; 15(5):315-22.
  17. Izumi K, Mizokami A, Li YQ, Narimoto K, Sugimoto K, Kadono Y, Kitagawa Y, Konaka H, Koh E, Keller ET, Namiki M. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes. *Prostate.* 2009 Aug 1; 69(11):1222-34.
  18. Kanagawa K, Sugimura K, Kuratsukuri K, Ikemoto S, Kishimoto T, Nakatani T. Norepinephrine activates P44 and P42 MAPK in human prostate stromal and smooth muscle cells but not in epithelial cells. *Prostate.* 2003 Sep 1; 56(4):313-8.
  19. King KJ, Nicholson HD, Assinder SJ. Effect of increasing ration of estrogen: androgen on proliferation of normal human prostate stromal and epithelial cells, and the malignant cell line LNCaP. 2006 Jan 1; 66(1):105-14.
  20. Kuzmin I, Gillespie JW, Protopopov A, Geil L, Dreijerink K, Yang Y, Vocke CD, Duh f-M, Zabarovsky E, Minna JD, Rhim JS, Emmert-Buck MR, Lineham WM, Lerman MI. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. *Canc Res.* 2005 Jun 15; 62:3498-502.
  21. Le H, Arnold JT, McFann KK, Blackman MR. DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells. *Am J Physiol Endocrinol Metab.* 2006; 290(5):E952-60.
  22. Liu X, Allen JD, Arnold JT, Blackman MR. Lycopene inhibits IGF-I signal transduction and growth in normal prostate epithelial cells by decreasing DHT-modulated IGF-I production in co-cultured reactive stromal cells. *Carcinogenesis.* 2008 Apr; 29(4):816-23.
  23. Maeda H, Hori S, Ohizumi H, Segawa T, Kakehi Y, Ogawa O, Kakizuka A. Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine. *Cell Death Differ.* 2004 Jul; 11(7):737-46.
  24. Mertz KD, Setlur SR, Dhanasekaran SM, Demichelis F, Perner S, Tomlins S, Tchinda J, Laxman B, Vessella RL, Beroukhi R, Lee C, Chinnaiyan AM, Rubin MA. Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate



- cancer cell line: a new perspective for an old model. *Neoplasia*. 2007 Mar; 9(3):200-6.
25. Nagakawa O, Junicho A, Akashi T, Koizumi K, Matsuda T, Fuse H, Saiki I. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells. *Oncol Rep*. 2005 Jun; 13(6):1217-21.
  26. Satoh M, Wang H, Ishidoya S, Abe H, Moriya T, Hamada H, Arai Y. Oncolytic virotherapy for prostate cancer by E1A, E1B mutant adenovirus. *Urology*. 2007 Dec; 70(6):1243-8.
  27. Schauer IG, Ressler SJ, Rowley DR. Keratinocyte-derived chemokine induces prostate epithelial hyperplasia and reactive stroma in a novel transgenic mouse model. *Prostate*. 2009 Mar 1; 69(4):373-84.
  28. Sen M, McHugh K, Hutzley J, Philips BJ, Dhir R, Parwani AV, Kelavkar UP. Orthotopic expression of human 15-lipoxygenase (LO)-1 in the dorsolateral prostate of normal wild-type C57BL/6 mouse causes PIN-like lesions. *Prostaglandins Other Lipid Mediat*. 2006 Oct; 81(1-2):1-13.
  29. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, Yang A, Montironi R, McKeon F, Loda M. p63 is a prostate basal cell marker and is required for prostate development. *Am J Pathol*. 2000 Dec; 157(6):1769-75.
  30. Subbarayan V, Sabichi AL, Llansa N, Lippman SM, Menter DG. Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells. *Cancer Res*. 2001 Mar 15; 61(6):2720-6.
  31. Uemura H, Ishiguro H, Nagashima Y, Sasaki T, Nakaigawa N, Hasumi H, Kato S, Kubota Y. Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells. *Mol Cancer Ther*. 2005 Nov; 4(11):1699-709.
  32. Urano T, Takahashi S, Suzuki T, Fujimura T, Fujita M, Kumagai J, Horie-Inoue K, Sasano H, Kitamura T, Ouchi Y, Inoue S. 14-3-3sigma is down-regulated in human prostate cancer. *Biochem Biophys Res Commun*. 2004 Jul 2; 319(3):795-800.
  33. van der Heul-Nieuwenhuijsen L, Dits NF, Jenster G. Gene expression of forkhead transcription factors in the normal and diseased human prostate. *BJU Int*. 2009 Jun; 103(11):1574-80.
  34. van der Heul-Nieuwenhuijsen L, Hendriksen PJ, van der Kwast TH, Jenster G. Gene expression profiling of the human prostate zones. *BJU Int*. 2006; 98(4):886-97.
  35. Verona EV, Elkahloun AG, Yang J, Bandyopadhyay A, Yeh IT, Sun LZ. Transforming growth factor-beta signaling in prostate stromal cells supports prostate carcinoma growth by up-regulating stromal genes related to tissue remodeling. *Cancer Res*. 2007 Jun 15; 67(12):5737-46.
  36. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Frierson HF, Hampton GM. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. *Cancer Res*. 2001; 61(16):5974-8.
  37. Whittington K, Assinder S, Gould M, Nicholson. Oxytocin, oxytocin-associated neurophysin and the oxytocin receptor in the human prostate. *Cell Tiss Res*. 2004 Nov; 318(2):375-82.
  38. Wu YM, Robinson DR, Kung HJ. Signal pathways in up-regulation of chemokines by tyrosine kinase MER/NYK in prostate cancer cells. *Cancer Res*. 2004; 64(20):7311-20.
  39. Zhu H, Mazor M, Kawano Y, Walker MM, Leung HY, Armstrong K, Waxman J, Kypta RM. Analysis of Wnt gene expression in prostate cancer: mutual inhibition by WNT11 and the androgen receptor. *Canc Res*. 2004 Nov 1; 64:7918-26.

## PrSMC

1. Adam RM, Borer JG, Williams J, Eastham JA, Loughlin KR, Freeman MR. Amphiregulin is coordinately expressed with heparin-binding epidermal growth factor-like growth factor in the interstitial smooth muscle of the human prostate. *Endocrinology*. 1999; 140(12):5866-75.
2. Butter S, Laping NJ, Pullen M, Grygielko E, Olson B, Brooks DP. The role of transforming growth factor-beta and its receptors in human prostate smooth muscle cell fibronectin production. *Eur J Pharmacol*. 2001 Jun 22; 422(1-3):47-52.
3. Han EKH, Lim JTE, Arber N, Rubin MA, Xing WQ, Weinstein B. Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. *Prostate*. 1998; 35(2):95-101.

4. Hisataki T, Itoh N, Suzuki K, Takahashi A, Masumori N, Tohse N, Ohmori Y, Yamada S, Tsukamoto. Modulation of phenotype of human prostatic stromal cells by transforming growth factor-betas. *Prostate*. 2004; 58(2):174-82.
5. Kanagawa K, Sugimura K, Kuratsukuri K, Ikemoto S, Kishimoto T, Nakatani T. Norepinephrine activates P44 and P42 MAPK in human prostate stromal and smooth muscle cells but not in epithelial cells. *Prostate*. 2003 Sep 1; 56(4):313-8.
6. Kim J, Yang P, Suraokar M, Sabichi AL, Llansa ND, Mendoza G, Subbarayan V, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. *Cancer Res*. 2005 Jul 15; 65(14):6189-98.
7. Sen M, McHugh K, Hutzley J, Philips BJ, Dhir R, Parwani AV, Kelavkar UP. Orthotopic expression of human 15-lipoxygenase (LO)-1 in the dorsolateral prostate of normal wild-type C57BL/6 mouse causes PIN-like lesions. *Prostaglandins Other Lipid Mediat*. 2006 Oct; 81(1-2):1-13.
8. Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF, Nelson WG. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. *Cancer Res*. 1999 Oct 15; 59(20):5160-8.
9. Subbarayan V, Sabichi AL, Llansa N, Lippman SM, Menter DG. Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells. *Cancer Res*. 2001 Mar 15; 61(6):2720-6.
10. Subbarayan V, Xu XC, Kim J, Yang P, Hoque A, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia. *Neoplasia*. 2005 Mar; 7(3):280-93.
11. Wu-Wong JR, Chiou WJ, Dickinson R, Opgenorth TJ. Endothelin attenuates

apoptosis in human smooth muscle cells. *Biochem J*. 1997; 328:733-7.

## Media

1. Alam TN, O'Hare MJ, Laczkó I, Freeman A, Al-Beidh F, Masters JR, Hudson DL. Differential expression of CD44 during human prostate epithelial cell differentiation. *J Histochem Cytochem*. 2004 Aug; 52(8):1083-90.
2. Fry PM, Hudson DL, O'Hare MJ, Masters JR. Comparison of marker protein expression in benign prostatic hyperplasia in vivo and in vitro. *BJU Int*. 2000 Mar; 85(4): 504-13.
3. Gmyrek GA, Walburg M, Webb CP, Yu H-M, You X, Vaughan ED, Vande Woude GF, Knudsen BS. Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. *Am J Pathol*. 2001; 159:579-90.
4. Hao J, McDaniel K, Weyer C, Barrera J, Nagle RB. Cell line-specific translation of two laminin 5 beta3 chain isoforms. *Gene*. 2002 Jan 23; 283(1-2):237-44.
5. Harvey HA, Jennings MP, Campbell CA, Williams R, Apicella MA. Receptor-mediated endocytosis of *Neisseria gonorrhoeae* into primary human urethral epithelial cells: the role of the asialoglycoprotein receptor. *Mol Microbiol*. 2001 Nov; 42(3):659-72.
6. Harvey HA, Post DM, Apicella MA. immortalization of human urethral epithelial cells: a model for the study of the pathogenesis of and the inflammatory cytokine response to *Neisseria gonorrhoeae* infection. *Infect Immun*. 2002 Oct; 70(10):5808-15.
7. Post DM, Phillips NJ, Shao JQ, Entz DD, Gibson BW, Apicella MA. Intracellular survival of *Neisseria gonorrhoeae* in male urethral epithelial cells: importance of a hexaacyl lipid A. *Infect Immun*. 2002 Feb; 70(2):909-20.
8. Sabbisetti V, Di Napoli A, Seeley A, Amato AM, O'Regan E, Ghebremichael M, Loda M, Signoretti S. p63 promotes cell survival through fatty acid synthase. *PLoS One*. 2009 Jun 11; 4(6):e5877.
9. Wilkes MC, Murphy SJ, Garamszegi N, Leof EB. Cell-type-specific activation of PAK2 by transforming growth factor beta independent of Smad2 and Smad3. *Mol Cell Biol*. 2003 Dec; 23(23):8878-89.

10. You Z, Dong Y, Kong X, Zhang Y, Vessella RL, Melamed J. Differential expression of IL-17RC isoforms in androgen-dependent and androgen-independent prostate cancers. *Neoplasia*. 2007 Jun; 9(6):464-70.
11. You Z, Shi XB, DuRaine G, Haudenschild D, Tepper CG, Lo SH, Gandour-Edwards R, de Vere White RW, Reddi AH. Interleukin-17 receptor-like gene is a novel antiapoptotic gene highly expressed in androgen-independent prostate cancer. *Cancer Res*. 2006 Jan 1;66(1):175-83.
12. Zhoul J, Hernandez G, Tu SW, Huang CL, Tseng CP, Hsieh JT. The role of DOC-2/DAB2 in modulating androgen receptor-mediated cell growth via the nongenomic c-Src-mediated pathway in normal prostatic epithelium and cancer. *Cancer Res*. 2005 Nov 1; 65(21):9906-13.

\* References not specifically citing the use of Lonza cells, media, or reagents in their research.

+ Denotes sections containing only the articles published within the last ten years.